Cytel launches Phase II clinical trials with Cylexin(TM) in myocardial infarction.SAN DIEGO--(BUSINESS WIRE)--Dec. 15, 1994--Cytel Corp. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :CYTL) Thursday announced the launch of Phase II clinical trials with its cell adhesion blocker, Cylexin(TM) (formerly known as CY-1503) in the setting of acute myocardial infarction acute myocardial infarction (  ·kyōōtˑ mī·ō·karˑ·dē· . Cylexin is a carbohydrate-based small molecule drug designed to treat tissue damage resulting from acute inflammation and reperfusion re·per·fu·sion n. The restoration of blood flow to an organ or tissue that has had its blood supply cut off, as after a heart attack. of previously ischemic Ischemic An inadequate supply of blood to a part of the body, caused by partial or total blockage of an artery. Mentioned in: Antiangiogenic Therapy, Subarachnoid Hemorrhage, Ventricular Fibrillation ischemic organs. The multi-center trial is being conducted under the direction of Joseph M. Sutton, MD., director of Acute Coronary Intervention, Cleveland Clinic Foundation, and will evaluate the ability of Cylexin to prevent cardiac reperfusion injury during the treatment of acute myocardial infarction with primary angioplasty. Cylexin has been shown in preclinical studies to reduce tissue damage which results from reperfusion of organs like the heart and lungs upon restoration of blood flow. In such studies, tissue damage was reduced by up to 70 percent when Cylexin was administered prior to opening the coronary artery. "We have confirmed this effect at The Cleveland Clinic in a model which more closely mimics human heart attack lesions with both underlying blockage and superimposed blood clot. I am very excited to begin clinical testing of this drug in patients presenting with heart attacks, in hopes we will affect a similarly dramatic limitation in final heart attack size. "The clinical implication of this drug is profound, since we have reached a therapeutic plateau in the salvage afforded by today's standard therapy," said Sutton. Cylexin is also being evaluated for its ability to reduce reperfusion injury following surgical removal of blood clots from the lungs by a procedure called pulmonary thromboendarterectomy (PTE PTE The ISO 4217 currency code for the Portugese Escudo. ). The PTE trial, which was launched in August at the University of California, San Diego UCSD is consistently ranked among the top ten public universities for undergraduate education in the United States by U.S. News & World Report.[3] It is a Public Ivy. [1] For graduate studies, most of UCSD's Ph.D. , targets an acute form of reperfusion lung injury which is clinically similar to Adult Respiratory Distress Syndrome Adult Respiratory Distress Syndrome Definition Adult respiratory distress syndrome (ARDS), also called acute respiratory distress syndrome, is a type of lung (pulmonary) failure that may result from any disease that causes large amounts of fluid to (ARDS Ards District (pop., 2001: 73,244), Northern Ireland. Formerly part of County Down, Ards was established as a district in 1973. Much of its land is devoted to crops and pasture. Newtownards, settled c. 1608 by Scots, is its administrative seat and manufacturing centre. ). Cytel, founded in 1987, is a leader in the discovery, design and development of immunotherapeutics, a new class of drugs which the company believes will be more selective and have fewer side-effects than drugs currently on the market. Utilizing Cytel's advanced understanding of the immune system's operation both in disease and in health, the company is developing drug candidates under two distinct approaches: the cell adhesion program is directed to the suppression of an inappropriate immune response to treat inflammatory diseases, and the immune stimulation program is directed to the development of therapeutic vaccines to treat infectious diseases and cancers. CONTACT: Cytel Corp., San Diego Jay D. Kranzler/Karin Eastham, 619/552-3000 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion